China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed the generic quality consistency evaluation (GQCE), making it the first generic version of the drug to achieve this status in China. The drug is used to treat acute mild (edematous) pancreatitis and as adjuvant therapy for acute hemorrhagic necrotizing pancreatitis.
Drug Background
Gabexate, a non-peptidic proteolytic enzyme inhibitor developed in the 1970s, is the world’s first chemical used to treat pancreatitis. Studies have shown that gabexate mesylate can rapidly and effectively inhibit the activities of various proteolytic enzymes. It also effectively inhibits the movement of the sphincter of Oddi and directly inhibits the inflammatory response. As an emergency medicine for acute pancreatitis, gabexate is recommended by multiple guidelines and is included in the National Reimbursement Drug List (NRDL) in China. Notably, it is the only protease inhibitor without an NRDL reimbursement limit.-Fineline Info & Tech
